Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 4/20 | 0.37 |
| ▸ | CA2 | P00918 | 4/20 | 0.37 |
| ▸ | CA9 | Q16790 | 4/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | G6PD | P11413 | 1/20 | 0.35 |
| ▸ | IDE | P14735 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19844938 | 0.78 | MAPT (0.46) | MAPTLMNACA12CA2CA9 | |
| SCHEMBL19844935 | 0.74 | THRB (0.37) | MAPTLMNAPTGS2POLBCYP2D6 | |
| SCHEMBL19844939 | 0.74 | ALDH1A1 (0.43) | MAPTCA2RAB9ASMN1; SMN2 | |
| SCHEMBL5355231 | 0.73 | ENPP2 (0.75) | MAPTENPP2LMNACA12CA2 | |
| SCHEMBL5355235 | 0.73 | ENPP2 (0.75) | MAPTENPP2LMNACA12CA2 | |
| SCHEMBL2376239 | 0.72 | ENPP2 (0.72) | ENPP2PTGS2 | |
| SCHEMBL7056902 | 0.72 | ENPP2 (0.52) | MAPTENPP2CA12CA2CA9 | |
| SCHEMBL13074567 | 0.72 | NPC1 (0.43) | MAPTLMNAPOLBCYP2D6MEN1 | |
| SCHEMBL5316865 | 0.72 | ENPP2 (0.52) | MAPTENPP2PTGS2SMN1; SMN2 | |
| SCHEMBL14419936 | 0.71 | NPC1 (0.71) | MAPTCA12CA2CA9PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11155568-B2 | Bioadhesives | NUTECH VENTURES (US) | 2021-10-26 | — | — | US | disclosed |
| US-20200095270-A1 | METHODS OF MAKING AND USING LIGNIN DERIVATIVES | NUTECH VENTURES | 2020-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155568-B2 | Bioadhesives | EPCAM, VCAM1, SELP | MAPT 1598/4885ENPP2 3055/4885LMNA 941/4885 |
| US-20200095270-A1 | METHODS OF MAKING AND USING LIGNIN DERIVATIVES | HLCS, LOX, DCXR | MAPT 1550/4885ENPP2 4006/4885LMNA 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.